Martin Kankam
Internal Medicine · Leavenworth, KSNPI 1588612758
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,500 of the $1,500 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Pfizer.
Across 1 payment — averaging $1500.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
Across 681 payments — averaging $93,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$24M
- Avanir Pharmaceuticals, Inc.$8.5M
- Vertex$7.5M
- Eli Lilly$5M
- Merck$4.7M
- Takeda Pharmaceuticals U.S.A., Inc.$2.4M
- plus $11.4M from 17 others
What the payments were for
- Speaking & faculty fees$1,500100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $1,500 |
How this compares
$1,500 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Leavenworth
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
- Raed Al RajabiWestwood$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.